Yoshizumi Kazuki, Kimura Takashi, Ukon Shinichiro, Watanabe Shohei, Kasama Shuhei, Takeda Masanaka
Department of Internal Medicine, Division of Neurology, Hyogo College of Medicine.
Rinsho Shinkeigaku. 2020 Dec 26;60(12):865-868. doi: 10.5692/clinicalneurol.cn-001483. Epub 2020 Nov 20.
A 40-year-old male patient was diagnosed with invasive thymoma and myasthenia gravis in 2015. In 2016 and 2017, he experienced myasthenic crises, with an increase in size of invasive thymoma. In 2018, he received chemotherapy for the invasive thymoma. After 2 months, his symptoms rapidly progressed to myasthenic crisis with severe bulbar and respiratory symptoms, despite the significant effect of chemotherapy for the thymoma. High-dose corticosteroid, multiple plasma exchanges, and intravenous immunoglobulin did not improve the symptoms. Thus, eculizumab was administered, resulting in an improvement in his conditions. To our knowledge, this is the first report showing that eculizumab may improve myasthenic crisis with invasive thymoma.
一名40岁男性患者于2015年被诊断为侵袭性胸腺瘤合并重症肌无力。2016年和2017年，他经历了重症肌无力危象，侵袭性胸腺瘤体积增大。2018年，他接受了侵袭性胸腺瘤的化疗。2个月后，尽管化疗对胸腺瘤有显著效果，但他的症状迅速进展为伴有严重延髓和呼吸症状的重症肌无力危象。大剂量皮质类固醇、多次血浆置换和静脉注射免疫球蛋白均未改善症状。因此，给予依库珠单抗治疗，病情得到改善。据我们所知，这是第一份表明依库珠单抗可能改善侵袭性胸腺瘤所致重症肌无力危象的报告。
